I ask this in all honesty as it's a common refrain after biotech blow ups.
But funding and patients are finite, meaning that companies who drag out the development of inefficacious drugs end up sucking resources from the system.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.